The adjustment comes after Axsome announced a patent settlement regarding its antidepressant drug, Auvelity. The settlement terms grant a license to Teva Pharmaceuticals, allowing them to ...

The litigation resulted from submission by Teva of an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of AUVELITY in ...

Like most other drugs, Auvelity can cause side effects. Hair loss was not reported in the drug’s studies, but it has been reported since the drug was made available on the market. Auvelity can ...

Axsome grants Teva a license to sell generic Auvelity starting in 2038 or 2039, resolving all ongoing patent litigation. Axsome's Q4 and full-year 2024 Auvelity sales are expected at $92.6M and $ ...

Total net product revenue reached $386 million for 2024, with CEO Tabuteau stating, "Based on the recent performance, Auvelity is on track to reach blockbuster potential." Symbravo received FDA ...

Teva stock dropped 1%. The settlement, which resolves all outstanding patent litigation relating to Auvelity, will be submitted for review by the U.S. Federal Trade Commission and Department of ...

Axsome's Auvelity and Sunosi are crucial, with Auvelity expected to generate over 75% of 2025 revenues; as such, today's news is a significant win. Despite high competition in MDD and other ...

The quarter was marked by strong sales from its commercial products, Auvelity and Sunosi, and heightened strategic investment in research and development (R&D) reflected in increased spending.